<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33334">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01744119</url>
  </required_header>
  <id_info>
    <org_study_id>ANA-PMS001</org_study_id>
    <nct_id>NCT01744119</nct_id>
  </id_info>
  <brief_title>Vascutek Anaconda™ Abdominal Aortic Aneurysm (AAA) Post-Market Surveillance Registry</brief_title>
  <official_title>Vascutek Anaconda™ Stent Graft System for Infra-Renal Abdominal Aortic Aneurysm Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascutek Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascutek Ltd.</source>
  <oversight_info>
    <authority>United Kingdom: National Health Service</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational Post-Market Surveillance Registry is to gather post-market
      data on the performance of the CE marked Vascutek Anaconda™ Stent Graft System for the
      repair of Abdominal Aortic Aneurysms (AAA). The Study population consists of patients
      suitable for endovascular repair of AAA. Patients will be followed at 1, 3, 6, 12, 18, 24,
      36, 48 and 60 months post-implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vascutek Limited, a world leader in the development of vascular grafts, has combined their
      latest technological developments in polyester textile technology with unique endovascular
      design features to produce Anaconda™, the world's next generation of AAA stent graft
      systems. Intuitive and of a modular design, Anaconda™ is the only repositionable device
      which also features exceptional flexibility. The modular design comprises bifurcate bodies,
      iliac legs and aortic cuffs. Nitinol, an alloy of nickel and titanium, has self-expanding
      properties and forms the top &quot;ring-stent&quot; of the bifurcate body section. The &quot;ring stent&quot; is
      composed of multiple turns of Nitinol wire that provides significantly increased
      &quot;hoop-strength&quot; enabling a conformable and secure haemostatic seal against the vessel wall
      to be achieved. Nitinol hooks located adjacent to the &quot;ring stent&quot; anchor the graft in
      position thus preventing graft migration. The iliac limbs are fully supported with Nitinol
      and the bifurcate bodies feature a distal contra-lateral lumen Nitinol support, which in
      conjunction with a unique intrinsic magnet guidewire system facilitates cannulation of the
      bifurcate section.

      The system is available in a wide range of sizes thus making it a flexible and adaptable
      stent graft system with the potential to repair diverse patient anatomy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2005</start_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Evaluation of graft performance</measure>
    <time_frame>60 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data will be collected and analysed on system insertion and difficulty during deployment. Efficiency of the magnet system including magnet selection, ease of use and removal of magnet guidewire will also be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft patency</measure>
    <time_frame>60 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data will be collected and analysed on endoleak exclusion and graft migration rates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exclusion of aneurysm</measure>
    <time_frame>60 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Abdominal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Abdominal Aortic Aneurysm</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vascutek Anaconda™ Stent Graft System</intervention_name>
    <arm_group_label>Abdominal Aortic Aneurysm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients implanted with a CE-Marked Vascutek Anaconda™ Stent Graft System for Infra-Renal
        Abdominal Aortic Aneurysm Repair
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is implanted with Anaconda™ Stent Graft System

        Exclusion Criteria:

          -  Ruptured or symptomatic aneurysm

          -  Juxta or Suprarenal extension of aneurysm

          -  Clinically serious concomitant medical disease or infection

          -  Need to sacrifice both Internal Iliac Arteries due to aneurysmal dilatation

          -  Connective Tissue Disease (Marfan's Syndrome)

          -  ASA Rating of Grade IV or V

          -  Known allergy to Nitinol, Polyester or contrast medium

          -  Excessive tortuosity of access vessels (femoral or iliac arteries)

          -  Patients with aneurysm neck lengths of less than 15mm
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dalcross Private Hospital</name>
      <address>
        <city>Killara</city>
        <state>New South Wales</state>
        <zip>2071</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Richard Harris</last_name>
      <phone>(02) 9932 6600</phone>
    </contact>
    <investigator>
      <last_name>Dr Richard Harris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newcastle Private Medical Suites</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>NSW 2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Paul Myers</last_name>
      <phone>(02) 4952 5911</phone>
    </contact>
    <investigator>
      <last_name>Dr Paul Myers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr John Fletcher</last_name>
      <phone>(02)9845 5555</phone>
    </contact>
    <investigator>
      <last_name>Dr John Fletcher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Gary Fell</last_name>
      <phone>(03)9496 5000</phone>
    </contact>
    <investigator>
      <last_name>Dr Gary Fell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geelong Regional Vascular Service</name>
      <address>
        <city>Geelong</city>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr David Neale McClure</last_name>
      <phone>(03) 5229 0024</phone>
    </contact>
    <investigator>
      <last_name>Dr David Neale McClure</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Bibombe Patrice Mwipatayi</last_name>
      <phone>(08)9224 2244</phone>
    </contact>
    <investigator>
      <last_name>Dr Bibombe Patrice Mwipatayi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hollywood, Royal Perth</name>
      <address>
        <city>Perth</city>
        <zip>WA 6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Kishore Sieunarine</last_name>
      <phone>(08)9224 2244</phone>
    </contact>
    <investigator>
      <last_name>Dr Kishore Sieunarine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Guillaume De Varye</name>
      <address>
        <city>Saint Doulchard</city>
        <zip>18230</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Olivier Briand</last_name>
      <phone>0826 39 99 08</phone>
    </contact>
    <contact_backup>
      <last_name>Dr Darrieus</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr Olivier Briand</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Darrieus</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DRK Kliniken Mark Brandenburg</name>
      <address>
        <city>Berlin</city>
        <zip>13359</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Ingo Flessenkaemper</last_name>
      <phone>030 30356001</phone>
    </contact>
    <investigator>
      <last_name>Dr Ingo Flessenkaemper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>0167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Hans Florek</last_name>
      <phone>0351 480-0</phone>
    </contact>
    <investigator>
      <last_name>Dr Hans Florek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Reinhard Kopp</last_name>
      <phone>089 5160-0</phone>
    </contact>
    <investigator>
      <last_name>Dr Reinhard Kopp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Orsola - Bologna University</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Antonio Freyrie</last_name>
      <phone>+39 051 2099507</phone>
    </contact>
    <investigator>
      <last_name>Dr Antonio Freyrie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University federico II</name>
      <address>
        <city>Naples</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Giancarlo Bracale</last_name>
      <phone>081 676799</phone>
    </contact>
    <investigator>
      <last_name>Dr Giancarlo Bracale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guglielmo da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Ugo Ugolotti</last_name>
      <phone>0523 302366</phone>
    </contact>
    <investigator>
      <last_name>Dr Ugo Ugolotti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa di Cura Nuova Itor</name>
      <address>
        <city>Roma</city>
        <zip>00158</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Sante Camilli</last_name>
      <phone>06 416021</phone>
    </contact>
    <investigator>
      <last_name>Dr Sante Camilli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital, CDHB</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr David Lewis</last_name>
      <phone>(03) 364 0640</phone>
    </contact>
    <investigator>
      <last_name>Dr David Lewis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Thodur Vasudevan</last_name>
      <phone>(07) 839 8899</phone>
    </contact>
    <investigator>
      <last_name>Dr Thodur Vasudevan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Monteprincipe</name>
      <address>
        <city>Madrid</city>
        <zip>28660</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Luis Izquierdo Lamoca</last_name>
      <phone>917 08 99 00</phone>
    </contact>
    <investigator>
      <last_name>Dr Luis Izquierdo Lamoca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Peter Bungay</last_name>
      <phone>01332 340131</phone>
    </contact>
    <investigator>
      <last_name>Dr Peter Bungay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Richard Edwards</last_name>
      <phone>0141 211 3000</phone>
    </contact>
    <investigator>
      <last_name>Dr Richard Edwards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wishaw General Hospital</name>
      <address>
        <city>Wishaw</city>
        <zip>ML2 0DP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Donald Reid</last_name>
      <phone>01698 361100</phone>
    </contact>
    <investigator>
      <last_name>Dr Donald Reid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>November 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
